Rating Rationale
September 16, 2022 | Mumbai
Global Health Limited
Rating outlook revised to 'Positive'; Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities RatedRs.500 Crore
Long Term RatingCRISIL A+/Positive (Outlook Revised from ‘Stable’; Rating Reaffirmed)
Short Term RatingCRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has revised its outlook on the long-term bank facility of Global Health Limited (GHL) to Positive’ from 'Stable' while reaffirming the rating at ‘CRISIL A+’. The rating on the short-term bank facilities has been reaffirmed at ‘CRISIL A1+’.

 

The revision in outlook factors in the improvement in the business and financial risk profiles of the company, driven by faster-than-expected ramp-up of operations in the Lucknow hospital (housed in Medanta Holdings Pvt Ltd [MHPL; ‘CRISIL A/Positive’]), commissioning of the Patna hospital (housed in Global Health Patliputra Pvt Ltd [GHPPL; ‘CRISIL A/Positive’) in fiscal 2022 and improving operating performance of the flagship hospital in Gurugram (housed in GHL). On consolidated basis, revenue grew 50% year-on-year to Rs 2,177 crore in fiscal 2022 driven by higher occupancy of ~61% (~50% in fiscal 2021) on bed capacity of ~2,200 (~2,100 in fiscal 2021) and increase in average revenue per occupied bed (ARPOB). This, along with surge in elective surgeries in the latter half of fiscal 2022, resulted in operating margin of 21.8%. Although ARPOB is expected to moderate over the medium term, improvement in occupancy, ramp-up of operations of Patna hospital and introduction of new speciality treatments will enable the sustenance of operating margin at 20% over the medium term. 

 

The financial risk profile is supported by strong capital structure, healthy debt protection metrics and liquidity. Consolidated adjusted networth and gearing stood at Rs 1,610 crore and 0.5 time, respectively, as on March 31, 2022. GHL has planned capital expenditure (capex) of Rs ~1,000 crore over the next three fiscals for setting up a greenfield hospital in Noida (Rs 500-600 crore), capacity addition at Patna and Lucknow hospitals (Rs 200-300 crore) and regular maintenance. The capex will be funded through a prudent mix of cash accrual and debt. Even though the company will avail external debt, gearing is expected below 0.5 time over the medium term. Gross debt to earnings before interest, tax, depreciation and amortisation (Ebitda) ratio stood at 1.76 times in fiscal 2022 and is expected around 2.5 times over the medium term. Liquidity was healthy, supported by unencumbered liquid surplus of Rs 522 crore as on March 31, 2022. Furthermore, expected cash accrual of Rs 250-350 crore per annum over the next three fiscals is significantly higher than debt obligation ~Rs 300 crore till fiscal 2025 and maintenance capex.

 

The rating continue to reflect the company’s experienced management in therapeutic segments and healthy financial risk profile. These strengths are partially offset by risks related to implementation and timely stabilisation of upcoming hospitals, geographic and therapeutic segmental concentration in revenue and exposure to intense competition.

Analytical Approach

CRISIL Ratings has combined the business and financial risk profiles of GHL and its wholly owned subsidiaries, MHPL and GHPPL. These entities are collectively referred to herein as GHL.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

  • Experienced management and healthy operating capability: GHL benefits from the stewardship of Dr Naresh Trehan, one of the leading cardiac surgeons in India. Dr Trehan was instrumental in the establishment and management of Escorts Heart Institute & Research Centre (Escorts). His 20 years at the helm of Escorts were spent in pioneering initiatives for the development of healthcare delivery in India and research in cardiology. Also, the hospital has prominent doctors heading other therapeutic departments, such as orthopaedics, gastroenterology, neurology, and oncology, resulting in an established patient base. Revenue grew at compound annual rate of 10% during fiscal 2013 to 2022, supported by industry-leading revenue or bed rate, good occupancy and strong reputation. 

 

Revenue growth was sluggish in fiscal 2021 owing to the Covid-19 pandemic but recovered in fiscal 2022 aided by higher occupancy and ARPOB. Furthermore, the company’s dependence on the flagship Gurugram hospital (Medanta Medicity) is decreasing, with ramp-up of operations at Lucknow and Patna hospitals. The Lucknow hospital achieved operational break-even in fiscal 2022 and recorded 72% growth in revenue to Rs 380 crore, aided by improvement in occupancy and ARPOB. Operating margin for the Lucknow hospital improved to ~28% in fiscal 2022 (~16% in fiscal 2021). Consolidated operating margin is expected ~20% over the medium term.

 

  • Healthy financial risk profile: Financial risk profile is supported by a well-managed balance sheet, resulting in comfortable credit metrics. Net cash accrual to total debt and interest coverage ratios are estimated at 0.37 time and 6 times, respectively, in fiscal 2022. The debt to Ebitda ratio improved to 1.76 times in fiscal 2022 from 3.91 times in fiscal 2021. Despite slight moderation in Ebitda margin and incremental debt, gross debt to Ebitda ratio is expected around 2.5 times over the medium term. Furthermore, the management’s stance to maintain peak gearing below 0.5 time over the project implementation phase will ensure the balance sheet is not under material pressure.

 

Weaknesses:

  • Exposure to risks related to implementation and timely stabilisation of operations: The company has sizeable capex planned over the medium term, including setting up a greenfield hospital in Noida while expanding bed capacity to ~3,000 in existing hospitals by fiscal 2025.

 

The Patna hospital commenced operations in fiscal 2022 and recorded revenue of Rs 24 crore with Ebitda loss of Rs 26 crore. Fiscal 2023 will be the first full year of operations for this hospital; it is expected to achieve Ebitda break-even. Timely ramp-up and stabilisation of operations in the Patna hospital will remain key monitorables.

 

The company’s ability to set up and stabilise greenfield projects provides comfort in lieu of the new hospital in Noida. However, timely implementation without significant time and cost overruns will be a key monitorable.

 

  • Revenue concentration risk, and exposure to intense competition: Geographic and segment concentration in revenue persists. Increase in beds in new hospitals has helped to reduce concentration risk. Even though GHL has recently expanded operations to Lucknow and Patna, its flagship hospital will continue to be the key revenue and profitability driver over the medium term. This is because while the Lucknow hospital commenced operations in November 2019, the other hospitals in Ranchi and Indore are smaller and have modest occupancy. The Patna hospital should take another couple of years to scale up.

 

Although upcoming hospitals in New Delhi, National Capital Region and Uttar Pradesh will intensify competition in the healthcare space in the medium term, established hospitals, such as Medanta Medicity, are better placed to take on the competition, compared with mid-sized hospitals.

Liquidity: Strong

GHL has strong liquidity. The company’s cash accrual, expected at Rs 250-350 crore per annum over fiscals 2023 to 2025, will adequately cover debt obligation of about Rs 300 crore till fiscal 2025 and part-funding of sizeable capex. Liquidity is supported by healthy cash surplus of Rs 522 crore as on March 31, 2022.

Outlook: Positive

CRISIL Ratings believes GHL will benefit from higher bed count, stable occupancy and geographic diversification over the medium term. The business risk profile will benefit from revenue diversification from different multispecialty treatments. The financial risk profile will continue to be supported by increase in operating cash flow and prudent expansion. Proceeds from expected initial public offering (IPO) should strengthen the balance sheet.

Rating Sensitivity Factors

Upward factors

  • Successful implementation of capacity expansion and ramp up of operations at new hospitals, ensuring healthy revenue growth, and stable operating margin at 18%
  • Continued prudent funding of expansion plans leading to limited debt and comfortable debt metrics, with gross debt to Ebitda ratio of 2-2.5 times

 

Downward factors

  • Large, debt-funded capex weakening the debt protection metrics, with gross debt to Ebitda ratio above 3.25 times
  • Slower-than-expected ramp up at GHPPL, impacting overall cash accrual
  • Material reduction in liquidity

About the Company

GHL was established in 2004 by Dr Trehan. At present, Dr Trehan and his associates hold majority stake in GHL, and the balance is divided between Anant Investments (The Carlyle Group) and Dunearn Investments (Mauritius) Pte Ltd (Temasek Singapore Pte).

 

A world-class, super-specialty, tertiary-care hospital in Gurugram, Medanta Medicity, commenced operations in November 2009, and has capacity of over 1,400 beds and 40 operation theatres besides state-of-the-art diagnostic and laboratory facilities. In fiscal 2015, GHL entered into an arrangement to manage ~150 bed hospitals in Indore and Ranchi on lease. The company also operates hospitals in Lucknow and Patna under 100% subsidiaries, MHPL and GHPPL, respectively. The company is setting up a greenfield hospital in Noida. Consolidated operational bed count stood at ~1,800 as on March 31, 2022.

Key Financial Indicators

As on/for the period ended March 31 Unit  2022 2021
Revenue Rs.Crore 2177 1450
PAT Rs.Crore 196 29
PAT Margin % 8.99 2.01
Adjusted debt/adjusted networth Times 0.52 0.47
Interest coverage Times 5.94 3.58

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of

allotment

Coupon

rate (%)

Maturity

date

Issue size

(Rs.Crore)

Complexity

Level

Rating assigned

with outlook

NA

Proposed Long Term Bank Loan Facility

NA

NA

NA

340

NA

CRISIL A+/Positive

NA

Working Capital Facility

NA

NA

NA

100

NA

CRISIL A1+

NA

Non-Fund Based Limit

NA

NA

NA

60

NA

CRISIL A1+

Annexure - List of Entities Consolidated

Names of Entities Consolidated

Extent of Consolidation

Rationale for Consolidation

Medanta Holdings Pvt Ltd

Full

Common management and promoters, same business, and business and financial linkages

Global Health Patliputra Pvt Ltd

Full

Common management and promoters, same business, and business and financial linkages

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 440.0 CRISIL A1+ / CRISIL A+/Positive   -- 24-09-21 CRISIL A1+ / CRISIL A+/Stable 18-06-20 CRISIL A+/Stable 27-11-19 CRISIL A+/Positive CRISIL A+/Positive
      --   -- 18-06-21 CRISIL A1+ / CRISIL A+/Stable 22-05-20 CRISIL A+/Stable   -- --
Non-Fund Based Facilities ST 60.0 CRISIL A1+   -- 24-09-21 CRISIL A1+   --   -- --
      --   -- 18-06-21 CRISIL A1+   --   -- --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Non-Fund Based Limit 60 YES Bank Limited CRISIL A1+
Proposed Long Term Bank Loan Facility 340 Not Applicable CRISIL A+/Positive
Working Capital Facility 50 HDFC Bank Limited CRISIL A1+
Working Capital Facility 50 ICICI Bank Limited CRISIL A1+

This Annexure has been updated on 16-Sep-2022 in line with the lender-wise facility details as on 17-Dec-2021 received from the rated entity. 

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Poonam Upadhyay
Director
CRISIL Ratings Limited
D:+91 22 3342 3386
poonam.upadhyay@crisil.com


Rakhi Mahapatra
Manager
CRISIL Ratings Limited
B:+91 22 3342 3000
Rakhi.Mahapatra@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html